

# **Index**

- Laboratories (Illinois), 89
- Accreditation Board for Engineering and Technology, 140
- Acquired immunodeficiency syndrome (AIDS), 173, 178, 179, 183-184
- Agency for International Development, U.S. (AID)  
     research funding by, 8, 35, 47-48, 201  
     training activities funding by, 152
- Agriculture, plant, 13, 193, 215-216  
     AID funding of biotechnology-related R&D for, 48  
     barriers to commercialization in, 210-212  
     biotechniques used in, 194-197  
     biotechnology's impact on research investment in, 197-198  
     commercialization of biotechnical research involving, 209-212  
     funding biotechnical research for, 200-209  
     future research in, 212-213  
     impact of intellectual property protection on research investment in, 199-200  
     personnel needs for commercialization of, 211-212  
     policy issues and options involving, 213-215  
     USDA funding of biotechnology-related R&D for, 4, 44-45, 201-202
- Agricultural Research Service (ARS)-USDA  
     research funding by, 4, 44-45, 201-202  
     training activities funding by, 152, 201-202
- AgriGenetics Corp. (Ohio), 205
- Agro Ingredients, 81
- Alabama, biotechnology development by, 70
- American Cancer Society, 176
- American Council of Education, 140
- American Cyanamid Co. (New Jersey), 89
- American Institute of Chemical Engineers, 140
- American Society for Microbiology, 119
- Amgen (California)  
     collaborative ventures by, 89  
     intellectual property litigation by, 181
- Arbor Acres Farm, 89
- Arkansas, biotechnology development in, 68, 69, 70
- Arizona, biotechnology development in, 68, 70
- Arizona, University of, 49
- Bay State Skills Corporation (Massachusetts), 145, 153
- Ben Franklin Partnership Fund (Pennsylvania), 59, 66
- Bethlehem Steel Co. (Maryland), 233
- Biocatalysis Research Group (University of Iowa), 203
- Biological Sciences Complex (University of Georgia), 62, 121
- Biological Sciences Curriculum Study, 150
- BIONET, 38, 183-184
- Bioprocessing and Pharmaceutical Center (Philadelphia), 49
- Biosystems for Pollution Control Initiative (EPA), 226-238, 246
- BioTal, 234
- Biotechnica Ltd., 234
- Bio-Technology General, 87
- Biotechnology Institute (Penn State University), 59, 116, 147
- Biotechnology Process Engineering Center (BPEC)-MIT, 39, 40, 147, 151, 152, 173
- Biotechnology Program (Cornell University), 147
- Biotechnology Research and Development Corporation (Illinois), 205
- Biotechnology Task Force on Education, 142
- Bock, Richard, 87
- Branstad, Terry, 203
- Bureau of Labor Statistics, 133
- Burroughs-Wellcome (PLC), 102
- Calgene, Inc. (California)  
     collaborative ventures of, 89  
     revenue sources of, 81
- California  
     biotechnology development in, 8-9, 56, 61, 68, 69-70  
     litigation involving impact of federally funded research in, 208
- California Biotechnology, Inc., 172
- California State University, 140, 144, 145
- California, University of, 116, 208
- California, University of (Davis), 48, 149
- California, University of-Los Angeles (UCLA), 240
- Campbell Soup Co. (New Jersey), 81, 89
- Case Western Reserve University (Ohio), 147
- Catholic University of America (Washington, DC), 147
- Cedar Crest College (Pennsylvania), 144
- Center for Advanced Biotechnology Training in Cell and Molecular Biology (Catholic University), 147
- Center for Advanced Research in Biotechnology (CARB)-Maryland, 8, 46, 57, 62, 116, 117, 175
- Center for Biologic Evaluation and Research (FDA), 178, 179
- Center for Biotechnology Research (California), 116
- Center for Biotechnology (SUNY Stony Brook), 116, 117, 147, 148, 149-150
- Center for Environmental Biotechnology (University of Tennessee), 240
- Center for Separation Science (Arizona), 49
- Centocor (Pennsylvania), 163
- Cetus Corporation (California)  
     financing of 83, 85, 87  
     monoclonal antibody research by, 163  
     protein engineering research by, 166  
     revenues of, 82
- CIBA-GEIGY Corp., 81, 89, 205
- Cisneros, Henry, 56
- Cold Spring Harbor Laboratory (New York), 148, 149, 150, 152
- Collaborations  
     agri-biotechnical, 205  
     among U.S. biotechnology companies, 10, 87-90  
     between U.S./foreign companies, 10, 90-92  
     Federal interagency research, 17-18, 174-175, 202  
     structures of university/industry research, 115-118  
     trade-offs involving university/industry, 6-7, 114, 118-126  
     university/government, 6-7, 39, 40, 42, 43, 44, 46, 47-48, 49, 60, 63  
     university/industry, 6-7, 8, 20, 55, 66, 68-70, 113-126, 174  
     see also Research; Research and Development; individual participants in
- Colorado, biotechnology development in, 59, 62, 69
- Colorado State University (CSU), 48
- Columbia University (New York), 43, 57
- Commercialization  
     of agricultural biotechnical research, 209-212

- areas of primary focus for biotechnological, 9-10, 79-80  
barriers to biotechnology, 10-11, 97-109, 242-245  
factors influencing, of human therapeutics, 12, 168-185  
history of U.S. biotechnology, 9, 78-79  
policy options involving Tax Reform Act's incentives for biotechnological, 21-22  
State promotion of biotechnology, 55-57, 115  
university/industry collaborations and, 120  
Commodity Control List (CCL), 98, 99, 100  
Comprehensive Environmental Response, Compensation, and Liability Act-1980 (Public Law 96-510)(CERCLA), 224, 235, 239, 240  
Congressional Research Service, 108  
Connecticut, biotechnology development in, 62, 68, 69, 153  
Cooperative State Research Service (CSRS)-USDA  
  research funding by, 4, 44, 201-202  
  training activities funding by, 152, 201-202  
Coordinating Committee on Multilateral Export Controls (CoCOM), 97  
Cornell University (New York), 147, 239  
Corporate biotechnology companies (CBCs). See Industry; individual companies  
Council of State Governments, 70  
Crops. See Agriculture, plant  
Cystic Fibrosis Foundation, 176
- Darst/Imperial Chemical Industries (Iowa), 203  
Databases  
  biotechnology information, 38, 182-184  
  lack of agribiotechnical, 210  
  policy options relating to biotechnology, 187  
Dedicated biotechnology companies (DBC's)  
  agricultural R&D involvement by, 204, 209  
  biotechnology waste degradation, 273-277  
  collaboration with major corporations by, 87-92  
  financing, 10, 82-87, 88  
  R&D budgets of, 80  
  revenue sources of, 81-82  
  State distribution of, 67-68, 255-264  
  see also Industry  
Defense Advanced Research Projects Agency (DARPA)--DoD, 41  
Defense University Research Initiative (DURIP)--DoD, 42  
Department of Agriculture, U.S. (USDA)  
  agricultural investment return estimate by, 193-194  
  regulatory power of, 210  
  research allocation and process of, research grants, 205-206, 208-209  
  research funding by, 4, 7, 35, 44-45, 117, 201-202, 205  
  training activities funding by, 6, 152, 201-202  
Department of Commerce, U.S. (DOC)  
  DBC personnel estimate by, 132  
  research consortia promotion by, 104  
  research funding by, 45-47  
  technology transfer oversight by, 97, 98, 99, 100  
Department of Defense, U.S. (DoD)  
  research funding by, 4, 7, 35, 41-42, 174, 201  
  technology transfer oversight by, 97, 98-99, 100  
  training activities funding by, 152  
  waste generation by, 239
- Department of Energy, U.S. (DOE)  
  hazardous waste cleanup research projects, 239-240, 246  
  research funding by, 7, 35, 42-43, 174, 201, 202  
Department of the Interior, U. S., 240, 246  
Department of Justice, research consortia promotion by, 104  
*Diamond v. Chakrabarty*, 101, 199, 200  
DIRLINE, 183  
Drug Export Amendments Act-1986 (Public Law 99-660), 97, 98, 180-181  
Duke University (North Carolina), 175
- Eastman Kodak Co. (New York), 89  
Economic Recovery Act-1981 (ERTA) (Public Law 97-34), 105, 107, 115  
Ecova Corp. (Washington State), 235  
Education. See Training; Universities  
Eli Lilly & Company (Indiana), 161  
Embryogen, 123  
Endotronics, Inc. (Minnesota), 87  
Engenics, Inc. (California), 116  
Engineering Research Center (Duke University), 175  
Engineering Research Centers program (NSF), 39, 40  
Environmental Protection Agency, U.S. (EPA)  
  R&D strategies report by, 100  
  regulatory authority of, 210, 224-225  
  research funding by, 7, 35, 48, 236-239  
  Research Laboratories, 238-239  
  waste management R&D activities by, 236-239, 243-244, 246  
*Ex parte Hibberd*, 199  
Expenditures. See Funding  
Experimental Program to Stimulate Competitive Research (EPSCoR), 9, 70-71  
Export Administration Act (EAA)(Public Law 96-72), 97, 99-100  
Export Administration Act Amendments-1985 (EAAA)(Public Law 99-64), 97, 99
- Federal Food, Drug, and Cosmetics Act (FFDCA), 97, 177  
Feinstein, Dianne, 56  
Ferris State College (Michigan), 144  
Florida, biotechnology development in, 62, 65, 68  
Food and Drug Administration (FDA)  
  biotechnology regulatory policy of, 177  
  human therapeutics approval and regulation by, 12, 161, 162, 178-179  
  research funding by, 7, 50  
  technology transfer approval of, 97, 98
- Funding  
  agri-biotechnical research, 200-209  
  Federal biotechnological hazardous waste cleanup, 235-236, 237, 242-244, 245-246  
  Federal biotechnology-related, 3-5, 15-18, 22-23, 30-31, 35-52, 62, 70-71, 173-175, 201-202, 205-206, 208-209  
  impact on agricultural research investment of source of, 205-209  
  methods for DBCs, 10, 82-87, 88  
  private sector biotechnology research, 6, 31, 113, 175-177, 204-205, 207-208, 209  
  R&D, from Federal to State governments, 21, 57, 60-61, 70-71

- R&D involving human therapeutics, 173-177  
 State biotechnology-related, 4, 9, 55, 64-70, 175, 202-204
- GenBank**, 38, 51, 174, 187
- Genentech, Inc. (California)**, 77  
   Activase approval for, 178  
   effect of patent litigation on, 101-102, 181  
   financing of, 83, 86, 87, 176  
   recombinant DNA insulin developed by, 161  
   R&D expenditures of, 80  
   revenues of, 82
- General Accounting Office (GAO)**, 100
- General Agreement on Tariffs and Trade (GATT)**, 101
- General Electric Corp. (GE)-New York**, 234
- Genetic Engineering News**, 136
- Genetics Institute, Inc. (Massachusetts)**, 181
- Georgia, biotechnology development in**, 6, 62, 153
- Georgia, University of**, 62, 121
- Government, Federal**  
   biotechnology-related funding by, 3-5, 30-31, 35-52, 62, 70-71, 173-175, 201-202  
   biotechnology waste management research by, 235-240  
   cleanup of waste sites belonging to, 239  
   funding involving human therapeutics development, 173-175  
   funding of training activities by, 6, 151-153  
   R&D funding to States by, 21, 57, 60-61, 70-71  
   Superfund cleanup expenditures by, 223-224  
   support for agricultural research by, 13, 193-194, 201-202, 205-206, 208-209, 213-214  
   see also individual agencies of
- Government, local. See Government, State**
- Government, State**  
   agricultural research funding by, 202-204  
   biotechnology promotion by, 4, 8-9, 55-64, 115  
   biotechnology-related funding by, 4, 55, 64-70  
   Federal assistance to biotechnology efforts by, 2, 57, 60-61, 70-71  
   funding involving human therapeutics development by, 175  
   funding of training activities by, 6, 150-151, 153  
   fund-raising mechanisms of, 66-67  
   incentives to biotechnology companies by, 67-70
- Guidelines**  
   biotechnology regulatory, 46-47, 101  
   land-grant system accountability, 208  
   policy options regarding university/industry research, 20  
   technology transfer, 7, 38  
   see also Regulation
- Harvard University (Massachusetts)**, 43, 124
- Hatch Act**, 208
- Hazardous and Solid Waste Amendments-1984 (HWSA)(Public Law 98-616)**, 224, 225
- Hazardous waste management**, 13-14, 223, 224, 247  
   barriers to biotechnology development for, 242-245  
   biotechnological applications for, 233-235  
   companies involved in (list of), 273-277  
   congressional issues and options involving, 245-247  
   onsite, 231-233  
   research needs for biotechnological, 48, 241-242  
   scientific base of biotechnology for, 225-233
- History of U.S. commercial biotechnology**, 9, 78-79
- Hoechst Corp.**, 118
- Hoffman-LaRoche, Inc. (New Jersey)**, 102, 181
- Howard Hughes Medical Institute (HHMI)**  
   biological education sponsorship by, 153  
   research funding by, 176-177
- Human Mutant Cell Repository (New Jersey)**, 38
- Human therapeutics**, 12, 161-162  
   biotechnological applications to, 162-167, 185  
   databases in biotechnological, 182-184  
   intellectual property protection for, 181-182  
   personnel availability for biotechnology applications to, 184-185  
   policy issues and options relevant to, 185-187  
   R&D funding for, 173-177  
   regulation of biotechnology involving, 177
- Hunt, James B.**, 59
- Idaho, biotechnology development in**, 62
- Illinois, biotechnology development in**, 59, 65, 69, 205, 207
- Illinois, University of**, 229
- Incentives**  
   to attract trained scientific personnel to PTO, 103  
   influencing human therapeutics development, 177-182  
   State, to attract biotechnology companies, 67-60  
   tax-based investment, 105-108
- Indiana, biotechnology development in**, 68-69, 70, 207
- Industrial Biotechnology Association (IBA)**, 105  
   personnel estimates by, 133, 136  
   secondary school teacher training by, 150
- Industry**  
   benefits and problems resulting from collaborations with universities by, 120, 123  
   biotechnology investment by large (list of corporations), 265-266  
   collaborative ventures in biotechnology by, 87-92  
   hazardous waste generated by, 223  
   human therapeutics development funding by, 175-176  
   pressures to develop alternative waste management solutions on, 223-235  
   profile of commercial biotechnology, 9-10, 78-82  
   research funding by, 6, 10, 31, 80-81, 113, 176-177, 204-205, 207-208, 209, 240-241, 243  
   training activities funding by, 6, 153  
   waste disposal costs of, 225  
   see also Commercialization; Dedicated biotechnology companies; Private sector
- Information Retrieval Experiment (IRX) program (NLM)**, 187
- Installation Restoration Program (IRP)(DoD)**, 239
- Institute of Medicine (IOM), DBCs personnel needs survey by**, 119, 131
- Intellectual property. See Patents; Trade secrets.**
- Investment. See Funding; Personnel; Training**
- In Vitro Cell Biology and Biotechnology Program (SUNY Plattsburgh)**, 144
- Iowa**  
   agricultural training investment by, 202, 203  
   biotechnology development in, 59, 66, 153, 202, 203, 207
- Iowa State University (ISU)**, 204

Iowa, University of, 140, 144, 203

Japan, collaborative biotechnology ventures with, 10, 90-91  
Johnson & Johnson (New Jersey), 89

Kansas, biotechnology development in, 59, 70

Kemira Oy Corp., 89

Kentucky, biotechnology development in, 9, 70, 71

Kentucky, University of, 144

Keystone Environmental Resources, Inc. (Pennsylvania), 234

Kidder Peabody & Co., 225

Kirin Brewery, 89

Koppers Company, 234

#### Legislation

affecting intellectual property issues, 101, 179-181, 185-187, 199-200

effect of antitrust, on R&D technology transfer, 104  
see also individual statutes

Lehigh University (Pennsylvania), 146

#### Litigation

concerning federally funded research in land-grant system, 208

involving intellectual property laws, 101-102, 181-182  
see also individual cases

Little, Arthur D., 224

Louisiana, biotechnology development in, 62, 68

Maryland, biotechnology development in, 57, 66, 68, 69, 153

Maryland Biotechnology Institute (MBI), 62, 116

Maryland, University of—Baltimore County (UMBC), 146, 147

Maryland, University of—College Park, CARB project participation by, 8, 46, 57, 62, 175

Massachusetts, biotechnology development in, 8-9, 56, 59, 62, 64, 66, 68, 69, 153

Massachusetts General Hospital, 118

Massachusetts Institute of Technology (MIT), 39, 40, 116

Matrix of Biological Knowledge, 184

Mendelian Inheritance in Man, 187

Michigan, biotechnology development in, 59, 65, 66, 68, 69, 207

Michigan Biotechnology Institute, 148

Midwest Plant Biotechnology Consortium (MPBC), 116, 207

Militarily Critical Technologies List (MCTL)—DoD, 98

Minnesota, biotechnology development in, 59, 207

Minnesota, University of, 146, 147

Missouri, biotechnology support by, 66, 207

#### Models

developing animal, for human protein function study, 171  
risk assessment, 48

Monitoring. See Regulation

Monoclonal Antibodies, Inc. (California), 82

Monoclonal Lymphocyte Technology Center (North Carolina), 174

Monsanto Agricultural Co., 6, 113, 123, 124

Montana, biotechnology development in, 9, 66, 71

Morehouse College, 240

Merrill Act—1862, 7, 60

National Academy of Sciences (NAS)

interdisciplinary training encouragement by, 184

protein folding and, 169

R&D personnel estimate by, 131

National Aeronautics and Space Administration (NASA)

research funding by, 7, 49, 201, 240

training activities funding by, 153

waste conversion research by, 240

National Bureau of Standards (NBS), research funding by, 8, 35, 46-47, 62, 175

National Cooperative Research Act—1984 (NCRA) (Public Law 98-462), 104, 115

National Huntington's Disease Association, 176

National Institutes of Health (NIH)

research funding by, 3, 7, 35, 37-38, 135, 173, 174, 240

training activities funding by, 6, 151-152, 206

waste management R&D by, 240, 246

National laboratories. See Department of Energy, U.S.

National Library of Medicine (NLM)(NIH), database coordination by, 183, 184, 187

National Oceanic and Atmospheric Administration (NOAA)

research funding by, 8, 35, 45-46

training activities funding by, 6, 153

National Research Council

biotechnology funding report by, 43

curriculum content survey by, 140

DNA mapping technologies development and, 168

National Science Foundation (NSF)

biotechnology R&D personnel estimate by, 132

research funding by, 4, 7, 35, 39-41, 60-61, 70-71, 115, 173-174, 201, 202

training activities funding by, 6, 151, 152, 202

waste bioremediation research by, 240, 246

Nebraska, biotechnology development in, 59

Nevada, EPSCoR grant to, 70

New Hampshire, biotechnology support by, 70

New Jersey, biotechnology development in, 4, 59, 64, 65, 66, 68, 69

New York State, biotechnology development in, 57, 59, 65-66, 68, 69, 70, 153

North Carolina

agricultural training investment by, 202

biotechnology development in, 4, 59, 62, 64, 65, 70, 17

North Carolina Biotechnology Center, 148, 150, 174, 175

North Carolina, University of—Chapel Hill, 148

North Dakota, biotechnology development in, 9, 70-71, 153

North Dakota State University (Fargo), 144

Occidental Chemical Corp. (New York), 234

Ohio, biotechnology development in, 66, 67, 68, 207

Ohio State University, 147

Ohio University, 123

Oklahoma, biotechnology development in, 9, 59, 70, 71

Oregon, biotechnology development in, 62

Oregon Health Sciences University, 62

Oregon State University, 62

Oregon, University of, 62

Orphan Drug Act—1983 (Public Law 97-414), 179-180, 185-187

- Ortho Pharmaceutical Corporation (New Jersey), 163
- Patent and Trademark Amendments Act—1980 (Public Law 96-517), 114, 200
- Patent and Trademark Amendments Act—1984 amendments (Public Law 98-620), 200
- Patent and Trademark Office, U.S. (PTO), 101, 103
- patentability criteria of, 182
  - plant patents granted by, 199
- Patents
- collaborative efforts and, 118-119, 120, 121, 123, 124, 125
  - effects of, on biotechnology development, 11, 101-103
  - human therapeutics development and, 181-182
  - plant protection using, 199-200, 211
- Pennsylvania, biotechnology promotion in, 4, 6, 59-60, 62, 65, 66-67, 68, 69, 153.
- Pennsylvania State University, 59, 116, 147
- Perot, H. Ross, 65
- Personnel, 5-6, 131, 153-154
- availability of trained, and U.S. pharmaceutical biotechnology superiority, 184-185
  - biotechnology's effect on types of trained agricultural, 198
  - current levels of biotechnology, 131-133
  - funding for training of, 6, 150-153, 202, 203
  - needs in biotechnology industry, 133-135, 211-212
  - potential shortages in biotechnology, 135-137, 244-245
  - turnover and workload trends for PTO, 103
  - university/industry collaboration and, 119-120
- Pharmaceuticals. *See* Human therapeutics
- Philanthropic organizations. *See* individual organizations.
- Philip Morris Company, 81, 89
- Pioneer Hi-Bred International (Iowa), 203
- Pittsburgh Biomedical Research Center (University of Pittsburgh), 59
- Pittsburgh Technology Center, Biotechnology Center of, 59-60
- Pittsburgh, University of, 59
- Plant Patent Act—1930 (U.S.C. §§ 161-164) (PPA), 199, 211
- Plant Variety Protection Act—1970 (7 U.S.C. §2321 et seq.) (PVPA), 199, 200, 211
- Plants. *See* Agriculture, plant
- Policy
- FDA biotechnology regulatory, 177
  - issues and options for Congress, 14-23, 185-187, 213-215, 245-247
  - trade, 10, 97-100
- Pramer, David, 138
- Private sector
- funding of research, 6, 31, 113, 175-177, 204-205, 207-208, 209
  - waste management R&D by, 240-241, 243
  - see also* Industry; individual philanthropic organizations
- Procter & Gamble Co. (Ohio), 81, 89
- Program in Molecular Biology and Biotechnology (University of North Carolina), 148
- Proprietary information. *See* Patents; Trade secrets
- Protein Information Resource databank, 187
- Public Health Service Act (PHSA), 177
- Puerto Rico, EPSCoR grant to, 70
- Regulation
- effect on public stock offerings of, 87, 101-102, 181-82
  - effects of governmental, on biotechnology development, 100-101, 210-211
  - of pharmaceutical biotechnology, 177-181
  - private sector waste management investment and, 240
  - of university/industry collaborations, 7, 126
  - of waste management activities, 224-225, 240, 244
- Research
- access to biotechnology data derived from, 182-184, 187
  - agri-biotechnical, 13, 193, 215-216
  - applications of biotechnology applied to human therapeutics, 162-167, 185
  - benefits and problems of university/industry collaborations in, 118-123
  - biotechniques used in agricultural, 194-197
  - biotechnology's impact on investment in agriculture, 197-198
  - consortia, 104, 116
  - factors affecting investment in agri-biotechnical, 193-194, 199-200
  - factors influencing commercialization of human therapeutics, 12, 168-185
  - funding agri-biotechnical, 200-209, 213-214
  - future of agri-biotechnical, 212-213
  - gaps in basic and applied, applicable to human therapeutics development, 168-172
  - predictive risk assessment modeling, 48
  - State promotion of biotechnology, 4, 8-9, 55-64, 115
  - trends in university/industry collaborative, 114-115
  - types of collaborative arrangements for, 115-117
  - see also* Collaborations; Funding; Research and development (R&D)
- Research and development (R&D)
- areas of focus for biotechnology companies in, 9-10, 79-80
  - Federal funding to States for, 21, 57, 60-61, 70-71
  - funding for waste management, 235-241
  - funding involving human therapeutics development, 173-177
  - investment by biotechnology firms, 10, 80-81
  - microbial physiology and ecology, 230-231
  - needs for biotechnological waste management, 241-242
  - private sector financing of biotechnology, 10, 80-92
  - private sector funding of agri-biotechnical, 204-205, 207-208
  - State support of, 68-70
  - see also* Collaborations; Research
- Research and Development Limited Partnerships (RDLPs), 84-85, 105, 115
- Resources Conservation and Recovery Act—1976 (Public Law 94-580) (RCRA), 224, 225, 246
- Rhone-Poulenc Agrochimie, 81, 89
- Risk assessment, biotechnology-related research funding for, 48
- Rochester Institute of Technology (RIT), 143
- Roussel-Uclaf Corp., 89
- Ruckelshaus, William, 101
- Rutgers University (New Jersey), 144, 145, 147
- San Diego State University, 140, 144-145, 146
- San Francisco State University, 144, 145
- San Jose State University (SJSU), 149
- Small Business Administration Development Act—1982 (Public Law 97-219), 50, 51

- Small Business Innovation Research (SBIR) program, R&D funding by, 8, 35, 50-51, 70, 173, 174
- SmithKline Beckman, 89
- South Carolina, biotechnology development in, 61-62
- Standards. See Guidelines; Regulation
- Stanford University (California), 116
- State University of New York, 116, 117, 143-144, 147, 148, 149-150
- Stevenson-Wydler Technology Innovation Act-1980 (Public Law 96-480), 114
- Strategic alliances. See Collaborations
- Superfund, 224, 235, 239, 240
- Superfund Amendments and Reauthorization Act-1986 (Public Law 99-499) (SARA), 224, 225, 240
- Superfund Innovative Technology Evaluation (SITE) Program, 236, 246, 247
- Tax Reform Act-1986 (TRA) (Public Law 99-514), impact on biotechnology investment of, 11, 21-22, 84-85, 105-108
- Technical Advisory Committee (TAC)--DOC, biotechnology, 99
- Technology transfer  
   antitrust considerations and, 104  
   biotechnology development and, 23, 97-100  
   trade policy and, 97-100  
   U.S./Foreign collaborative ventures and, 90
- Technology Transfer Act-1986 (Public Law 99-502), 7, 38
- Tennessee, biotechnology development in, 62, 69
- Tennessee, University of--Knoxville, 240
- Texaco, Inc., 89
- Texas, biotechnology development in, 56, 61, 65
- Texas, University of, 56
- Toxic Substances Control Act-1976 (Public Law 94-469) (TSCA), 224
- Trade secrets  
   as alternative to patenting, 103, 182  
   plant protection using, 199, 211  
   university/industry collaborations and, 7, 115, 121, 122, 124, 125
- Training  
   biotechnicians at community colleges, 140-143  
   biotechnology's effect on agriculture personnel, 198  
   funding of biotechnology, 6, 18-20, 37, 39-40, 48, 150-153, 202, 203  
   interdisciplinary, 184  
   secondary school biotechnology, 149-150  
   university/industry collaboration and, 119-120  
   university initiatives in biotechnology, 6, 138-139, 267-272
- TreatTek, 234
- Tufts University (Massachusetts), 145, 146, 147, 149
- United Kingdom, patent litigation in, 181
- Universal Foods Corp. (Wisconsin), 59
- University City Science Center (Pennsylvania), 49
- Universities  
   benefits and problems resulting from collaborations with industry by, 118-120, 121-123  
   biotechnology education and training by, 6, 138-149, 267-272  
   role of, in State biotechnology programs, 60-63  
   see also individual universities; individual university biotechnology initiatives
- UpJohn Co., 89
- Utah, biotechnology development in, 59, 65
- Vaccines. See Human therapeutics
- Vermont, biotechnology development in, 9, 70
- Veterans Administration (VA), research funding by, 8, 49
- Virginia, biotechnology development in, 59, 69
- Washington University (Missouri), 6, 113, 123, 124
- Waste treatment. See Hazardous waste treatment
- Wellcome Foundation (U.K.), 181
- West Virginia, biotechnology development in, 59
- W.H. Miner Agricultural Center (SUNY Plattsburgh), 144
- Wisconsin Biotechnology Center (University of Wisconsin), 116, 117, 147
- Wisconsin Biotechnology Center Biopulping Consortium, 116, 117
- Wisconsin, biotechnology development in, 59, 62, 68, 70, 117, 207
- Wisconsin, University of, 117, 148, 150
- Worcester Polytechnic Institute (Massachusetts), 147
- Wyoming, EPSCoR grant to, 70
- Xoma Corporation (California), 163
- Young, Arthur, 87